Profile data is unavailable for this security.
About the company
Cogent Biosciences, Inc. is a biotechnology company. The Company is focused on developing precision therapies for genetically defined diseases. The Company’s clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. In addition to bezuclastinib, the Company is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting mutations in FGFR2, ErbB2 and PI3Kα. SUMMIT is its randomized, global, multicenter, double-blind, placebo-controlled, multi-part Phase II clinical trial for patients with Non-AdvSM. APEX is an open-label, global, multicenter study evaluating the safety, efficacy, pharmacokinetic, and pharmacodynamic profiles of bezuclastinib.
- Revenue in USD (TTM)0.00
- Net income in USD-227.05m
- Incorporated2014
- Employees164.00
- LocationCogent Biosciences Inc275 Wyman Street, 3Rd FloorWALTHAM 02451United StatesUSA
- Phone+1 (617) 945-5576
- Websitehttps://www.cogentbio.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CARGO Therapeutics Inc | 0.00 | -147.71m | 1.03bn | 116.00 | -- | 2.35 | -- | -- | -3.47 | -3.47 | 0.00 | 9.51 | 0.00 | -- | -- | 0.00 | -53.66 | -- | -59.56 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -139.67 | -- | -- | -- |
| Relay Therapeutics Inc | 10.01m | -345.20m | 1.04bn | 294.00 | -- | 1.23 | -- | 103.72 | -2.61 | -2.61 | 0.076 | 5.03 | 0.0109 | -- | -- | 30,978.33 | -37.58 | -28.55 | -39.69 | -29.54 | -- | -- | -3,449.92 | -998.20 | -- | -- | 0.00 | -- | 1,749.82 | -- | -17.72 | -- | 19.59 | -- |
| Septerna Inc | 840.00 | -10.27k | 1.09bn | 68.00 | -- | -- | -- | 1,295,586.00 | -0.0003 | -0.0003 | 0.00002 | 0.0037 | -- | -- | -- | 12.35 | -- | -- | -- | -- | -- | -- | -792.86 | -- | -- | -- | 0.00 | -- | -- | -- | 102.06 | -- | -- | -- |
| MiMedx Group Inc | 342.81m | 90.79m | 1.11bn | 895.00 | 15.18 | 6.11 | 11.12 | 3.23 | 0.4961 | 0.4601 | 2.00 | 1.23 | 1.58 | 2.63 | 6.65 | 383,022.30 | 44.93 | -4.14 | 56.00 | -5.90 | 83.37 | 83.61 | 28.37 | -2.70 | 3.53 | 22.35 | 0.0951 | -- | 20.03 | -2.19 | 310.29 | -- | -26.47 | -- |
| 89bio Inc | 0.00 | -288.96m | 1.11bn | 70.00 | -- | 2.93 | -- | -- | -2.91 | -2.91 | 0.00 | 3.56 | 0.00 | -- | -- | 0.00 | -62.93 | -45.50 | -67.67 | -49.31 | -- | -- | -- | -- | -- | -- | 0.0859 | -- | -- | -- | -39.37 | -- | -36.58 | -- |
| Cogent Biosciences Inc | 0.00 | -227.05m | 1.12bn | 164.00 | -- | 4.31 | -- | -- | -2.48 | -2.48 | 0.00 | 3.41 | 0.00 | -- | -- | 0.00 | -55.22 | -49.53 | -60.02 | -54.94 | -- | -- | -- | -1,684.44 | -- | -- | 0.00 | -- | -- | -- | -37.20 | -- | 38.48 | -- |
| Arrivent Biopharma Inc | 0.00 | -74.89m | 1.15bn | 40.00 | -- | 3.86 | -- | -- | -2.46 | -2.46 | 0.00 | 8.85 | 0.00 | -- | -- | 0.00 | -29.50 | -- | -31.02 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -87.86 | -- | -- | -- |
| Zymeworks Inc | 62.20m | -113.67m | 1.15bn | 294.00 | -- | 3.18 | -- | 18.49 | -1.51 | -1.51 | 0.8306 | 5.23 | 0.1192 | -- | 1.37 | 228,672.80 | -21.79 | -22.58 | -25.64 | -26.90 | -- | -- | -182.75 | -91.17 | -- | -- | 0.00009 | -- | -81.57 | 7.47 | -195.44 | -- | 3.58 | -- |
| Applied Therapeutics Inc | -211.00k | -187.31m | 1.16bn | 37.00 | -- | 199.26 | -- | -- | -1.53 | -1.53 | -0.0017 | 0.0506 | -0.0028 | -- | -- | -8,440.00 | -246.85 | -140.37 | -- | -240.93 | -- | -- | -- | -4,476.42 | -- | -- | 0.00 | -- | -- | -- | -45.15 | -- | -- | -- |
| Bicara Therapeutics Inc | 0.00 | -64.84m | 1.17bn | 32.00 | -- | -- | -- | -- | -1.25 | -1.25 | 0.00 | 3.72 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -37.36 | -- | -- | -- |
| Aurinia Pharmaceuticals Inc | 207.11m | -50.35m | 1.19bn | 300.00 | -- | 3.26 | -- | 5.74 | -0.3508 | -0.3508 | 1.44 | 2.55 | 0.3862 | 0.8006 | 9.20 | 690,350.00 | -9.39 | -25.97 | -10.78 | -28.24 | 86.08 | -- | -24.31 | -137.64 | 4.82 | -- | 0.1778 | -- | 30.95 | 227.90 | 27.88 | -- | 57.11 | -- |
| Ardelyx Inc | 251.85m | -72.58m | 1.20bn | 267.00 | -- | 7.59 | -- | 4.77 | -0.3113 | -0.3113 | 1.08 | 0.6682 | 0.7664 | 3.76 | 5.22 | 943,254.70 | -22.09 | -46.14 | -26.72 | -57.32 | 85.16 | 88.15 | -28.82 | -240.87 | 3.87 | -5.94 | 0.3888 | -- | 138.61 | 116.66 | 1.70 | -- | 2.04 | -- |
| Pharvaris NV | 0.00 | -122.29m | 1.22bn | 82.00 | -- | 3.42 | -- | -- | -2.56 | -2.56 | 0.00 | 6.60 | 0.00 | -- | -- | 0.00 | -42.13 | -36.09 | -45.04 | -38.27 | -- | -- | -- | -- | -- | -- | 0.0004 | -- | -- | -- | -32.15 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Point72 Asset Management LPas of 30 Jun 2024 | 10.47m | 9.57% |
| Commodore Capital LPas of 30 Jun 2024 | 9.74m | 8.90% |
| Kynam Capital Management LPas of 30 Jun 2024 | 9.26m | 8.46% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 6.58m | 6.01% |
| Fairmount Funds Management LLCas of 30 Jun 2024 | 6.23m | 5.69% |
| Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 5.53m | 5.06% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 5.04m | 4.61% |
| Redmile Group LLCas of 30 Jun 2024 | 4.80m | 4.39% |
| Adage Capital Management LPas of 30 Jun 2024 | 4.25m | 3.88% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 3.84m | 3.51% |
